Thomas D Schmittgen

Thomas D Schmittgen Ph.D.

Professor and Chair and the V. Ravi Chandran Professor of Pharmaceutical Sciences

Department: Pharmaceutics
Business Phone: (352) 273-8028
Business Email: tschmittgen@cop.ufl.edu

About Thomas D Schmittgen

Thomas D. Schmittgen, Ph.D. is a professor in the Department of Pharmaceutics at the University of Florida in Gainesville. Dr. Schmittgen holds both undergraduate (Pharmacy) and graduate degrees (Pharmaceutics) from the Ohio State University. He was a National Research Service Award (NIH) postdoctoral fellow at the University of Southern California from 1992-1995. He served on the faculty at Washington State University College of Pharmacy from 1995-2002. Dr. Schmittgen returned to the Ohio State University in 2002 where he remained on the faculty for 13 years, serving as chair of the Division of Pharmaceutics from 2000-2015. Dr. Schmittgen was hired at the University of Florida in 2015 through the UF Preeminence Initiative.

Honors & Awards

Best basic science paper
2017 · University of Florida
Fellow
2016 · American Association of Pharmaceutical Scientists
Co-author of the 21st most cited scientific paper of all time
2014 · Reported in Nature, Oct. 2014
Inventor of the year
2011 · TechColumbus Innovation Awards
Individual National Research Service Award
1993-1995 · National Institutes of Health
Fellow
1990-1991 · Berlex

Research Profile

Dr. Schmittgen’s research focuses on noncoding RNAs and cancer with emphasis on the use of microRNAs as therapeutic or diagnostic agents. A paper he co-authored in 2001 describing the relative method of gene quantification has been cited over 65,000 times and was recently ranked by the international journal Nature as the 21st most cited scientific article of all time. Dr. Schmittgen has been continuously funded by federal agencies (NIH, DOD) for the past 20 years. His lab was the first to establish a link between altered microRNA expression in pancreatic cancer. Dr. Schmittgen’s lab is currently developing exosomes/microvesicles as targeted drug delivery systems for the treatment of cancer. Dr. Schmittgen is a member of the American Association for Cancer Research, American Association for the Advancement of Science and is a Fellow of the American Association of Pharmaceutical Scientists.

Areas of Interest
  • Cancer
  • Drug delivery
  • Drug development
  • Exosomes
  • Extracellular vesicles
  • MircroRNA
  • RNA
  • Therapeutics

Grants

May 2019 – July 2019
Organize 12th Symposium on New Development in Clinical Pharmacy and Clinical Pharmacology
BOEHRINGER INGELHEIM PHARM INC · Principal Investigator
September 2018ACTIVE
2/3 Florida-California Cancer Research, Education & Engagement (CaRE2) Health Equity Center
NATL INST OF HLTH NCI ·
December 2017 – December 2018
Pfizer Agreement for Graduate Student Support
PFIZER INC · Principal Investigator
August 2017ACTIVE
The Novel Role of REST in the Development of Pancreatic Ductal Adenocarcinoma
NATL INST OF HLTH NCI · Mentor
August 2015 – July 2019
Targeted delivery of microRNA-loaded microvesicle for cancer therapy
NATL INST OF HLTH NCATS · Principal Investigator
December 2004ACTIVE
Pfizer Graduate Fellowship Award/Donation for PK/PD Study – Dr. Derendorf
PFIZER INC · Principal Investigator

Education

1995
Post Doc – Biochemistry & Molecular Biology
University of Southern California
1992
Ph.D. – Pharmaceutics
Ohio State University
1985
B.S. – Pharmacy
Ohio State University